
Advertise on podcast: GHAPPcast
Rating
5from
This podcast has
169 episodes
Language
EnglishExplicit
No
Date created
2023/06/14
Latest episode
2026/11/12
Average duration
13 min.
Release period
12 days
Description
This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).
Unlock GHAPPcast podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from GHAPPcast podcast
FAQ: HCV: Is It Still an Issue?
2026/11/12
Despite advances in hepatitis C treatment, why does hepatitis C virus (HCV) remain a significant public health concern, and what can healthcare providers do to improve diagnosis and access to care? In this educational video, Scott Springer, PA-C, a healthcare professional specializing in hepatology and addiction medicine in Buffalo, New York, discusses the ongoing challenges of hepatitis C screening, diagnosis, and treatment and the critical role advanced practice providers (APPs) can play in addressing gaps in care. Although highly effective direct-acting antiviral (DAA) therapies can cure most hepatitis C infections in just 8–12 weeks, many individuals remain undiagnosed or face barriers to accessing treatment. Springer explores strategies to simplify HCV screening and expand treatment opportunities across primary care, addiction medicine, gastroenterology, and hepatology settings. Learn how point-of-care hepatitis C testing, dried blood spot testing, reflex HCV RNA testing, and noninvasive liver fibrosis assessments, including the FIB-4 score, can help streamline diagnosis and reduce unnecessary patient visits. The discussion also highlights the importance of simplifying pretreatment evaluations, improving access to antiviral medications, and expanding hepatitis C treatment beyond specialty clinics. Discover how nurse practitioners, physician assistants, and other healthcare professionals can help close the gap between hepatitis C diagnosis and treatment, improve patient outcomes, and advance efforts toward hepatitis C elimination. Whether you work in hepatology, gastroenterology, primary care, or addiction medicine, this video provides practical insights into making hepatitis C care more accessible, efficient, and patient-centered.
Podcast: Keep Calm and Liver On
2026/11/10
What are the most common complications after liver transplantation, and how can healthcare providers recognize and manage them to improve patient outcomes? In this educational session from the 9th Annual GHAPP National Conference, Edith Johannes explores the clinical and emotional challenges patients face before and after liver transplant surgery. This discussion highlights the psychological impact of chronic liver disease, including grief, loss of independence, and the emotional journey from transplant evaluation to recovery. Learn about critical post-liver transplant complications, including primary graft nonfunction, early allograft dysfunction, hepatic artery thrombosis (HAT), ischemic cholangiopathy, biliary strictures, infections, and acute and chronic liver transplant rejection. The presentation examines the differences between early and late hepatic artery thrombosis, the importance of monitoring liver function tests (LFTs), and the role of magnetic resonance cholangiopancreatography (MRCP) and endoscopic retrograde cholangiopancreatography (ERCP) in diagnosing and treating biliary complications. Additional topics include immunosuppression-related infection risks, antibody-mediated rejection, donor-specific antibodies, and the long-term impact of medication nonadherence on graft survival. Discover why early recognition of transplant complications, careful interpretation of elevated liver enzymes, and timely clinical intervention are essential for protecting graft function and supporting long-term transplant success. Designed for hepatology nurse practitioners, physician assistants, gastroenterology providers, and other advanced practice providers (APPs), this session offers valuable insights into post-transplant monitoring, complication management, and the importance of addressing both the physical and psychological needs of liver transplant recipients.
Podcast: Behind the Scenes of GHAPP National Planning
2026/11/05
What does it take to bring one of the leading gastroenterology and hepatology conferences for advanced practice providers (APPs) to life? In this behind-the-scenes podcast, GHAPP board members Christina Hanson, FNP-C, Amy Ladewski, PA-C, and Patrick Horne, NP, share an inside look at the planning, collaboration, and dedication behind the GHAPP National Conference. From developing a comprehensive educational agenda and selecting relevant GI and hepatology topics to coordinating expert faculty, workshops, boot camps, and networking opportunities, discover how GHAPP continues to elevate professional education for nurse practitioners (NPs) and physician assistants (PAs). The discussion explores the evolution of GHAPP National over the past nine years, growing from approximately 100–150 attendees to more than 1,400 healthcare professionals, while maintaining its mission to educate, elevate, and empower APPs in gastroenterology and hepatology. Learn how this APP-led organization fosters mentorship, peer-to-peer learning, clinical collaboration, leadership development, and meaningful professional connections for both new and experienced GI and hepatology providers. The panel also highlights the importance of attendee feedback, innovative continuing medical education, and expanding access to educational resources through regional programs, podcasts, and scholarship opportunities. As GHAPP prepares to celebrate its 10th anniversary at GHAPP National 2027 in Dallas, hear what makes this conference a unique and supportive community for advanced practice providers dedicated to advancing GI and hepatology care.
Podcast: AI in GI: Hype, Help, or the Future
2026/11/03
How is artificial intelligence transforming gastroenterology, and is it truly improving patient care or simply generating hype? In this video, Sarah Enslin, PA-C, of the University of Rochester Medical Center, explores the evolving role of AI in gastroenterology and its potential to enhance clinical efficiency, diagnostic accuracy, and patient outcomes. From AI-assisted colonoscopy and computer-aided polyp detection (CADe) to computer-aided diagnosis (CADx), generative AI, and predictive analytics, discover how emerging technologies are shaping the future of GI practice. Sarah discusses how AI tools can support colorectal cancer screening, improve adenoma detection rates, streamline clinical documentation, and reduce administrative burdens for advanced practice providers (APPs). She also highlights practical applications of large language models, including ChatGPT and OpenEvidence, for clinical information synthesis and generating letters of medical necessity, as well as ambient AI documentation tools such as DAX Copilot.
Looking ahead, explore the potential of AI in pancreatic cancer detection, hepatocellular carcinoma risk prediction, personalized screening strategies, and electronic health record (EHR) workflow optimization. Learn how healthcare professionals can evaluate AI technologies based on FDA regulatory status, clinical evidence, real-world effectiveness, and meaningful patient outcomes while recognizing the importance of maintaining clinical judgment and oversight. Whether you're a gastroenterology nurse practitioner, physician assistant, or other healthcare professional, this discussion offers valuable insights into the benefits, limitations, and future of artificial intelligence in GI and hepatology.
Podcast: What is the GHAPP Peer Network?
2026/10/29
Discover the GHAPP Peer Network, a collaborative community designed to connect gastroenterology (GI), hepatology, and other advanced practice providers (APPs) nationwide. In this video, nurse practitioners HoChong Gilles, Oyin Penny, and Suzanne Robertazzi introduce the GHAPP Peer Network and explore how this innovative platform supports peer-to-peer learning, clinical collaboration, mentorship, and professional development beyond the GHAPP ACE 2.0 educational experience. Through the GHAPP ACE 2.0 app, healthcare professionals can connect with GI and hepatology experts, ask clinical questions, share educational resources, discover career opportunities, and engage with colleagues who share similar clinical interests and specialties. Whether you're an experienced nurse practitioner, a new APP entering gastroenterology or hepatology, or a primary care provider seeking specialty insights, the GHAPP Peer Network offers opportunities to expand your professional network, strengthen clinical knowledge, and translate education into everyday patient care. Learn how to create your profile, connect with mentors, explore upcoming educational events, and build meaningful professional relationships that extend beyond national conferences. Download the GHAPP ACE 2.0 app and join the Peer Network today to connect, collaborate, and grow alongside fellow healthcare professionals.
Linerixibat Medication Review
2026/09/22
Christina Hanson, FNP, and Dr. Marcelo Kugelmas of South Denver Gastroenterology review linerixibat, an ileal bile acid transporter (IBAT) inhibitor, and its role in managing cholestatic pruritus in primary biliary cholangitis (PBC). This medication review podcast explores how blocking bile acid reabsorption in the ileum targets a pathway involved in persistent itching. The discussion covers the phase 2 GLIMMER study and phase 3 GLISTEN trial, including findings on itch reduction, sleep interference, and treatment response in patients with moderate to severe pruritus. The speakers also examine safety and tolerability considerations, including diarrhea, abdominal pain, nausea, elevated liver enzymes, and treatment discontinuation. Additional topics include preliminary results from the linerixibat long-term safety and tolerability study (LLSAT), maintenance of itch relief, and the need for further research on combining linerixibat with PPAR agonists. Designed for nurse practitioners, physician assistants, and other gastroenterology and hepatology professionals, this episode offers a clinical perspective on IBAT inhibitor therapy, persistent PBC-related itching, and the balance between symptom improvement and treatment tolerability.
Clarifications and context within the video 👇
Linerixibat, an IBAT inhibitor, is the first FDA approved treatment for cholestatic pruritus in adults with PBC.WI-NRS is used to assess itch severity on a scale of 0-10.At 6:43, correction regarding the diagnosis of cirrhosis: It was 10% in the placebo group and 11% in the linerixibat group.At 10:24, the primary endpoints of the LLSAT study are frequency and severity of adverse events.At 11:20, the LLSAT mean WI-NRS reduction of 4.87 is for patients assigned to linerixibat in GLISTEN Part A and Part B after 52 weeks of continuous treatment.
Podcast: Managing Fatigue and Pruritus in Your Patients With PBC
2026/09/15
How can clinicians better recognize and manage itching and fatigue in primary biliary cholangitis (PBC)? In this podcast, hepatology clinicians from RUSH University Medical Center discuss the impact of PBC-related pruritus and fatigue on sleep, daily activities, and quality of life. The conversation explores proactive symptom screening, assessing itch severity, and individualizing treatment with options such as cholestyramine, PPAR therapies, rifampin, and sertraline. The speakers discuss how their treatment approaches have evolved and why ongoing communication helps identify when symptom management needs to change. For patients experiencing PBC fatigue, they address evaluating contributing factors such as thyroid dysfunction, vitamin D deficiency, and anemia, along with sleep hygiene, exercise, and realistic expectations for treatment. Throughout the discussion, they emphasize that symptom severity does not necessarily reflect liver disease progression or biochemical response. This episode highlights the importance of looking beyond liver tests, validating patients’ experiences, and encouraging patient advocacy and support networks as part of comprehensive PBC care.
Podcast: How to Screen and Diagnose Cholestatic Liver Diseases
2026/08/25
In this episode, HoChong Gilles of the Richmond VA Medical Center, and Alison Moe of Atlanta Gastroenterology discuss a practical, step-by-step approach to screening for and diagnosing cholestatic liver disease. The conversation reviews how to recognize a cholestatic liver test pattern, evaluate symptoms such as pruritus and jaundice, and confirm that an elevated alkaline phosphatase is hepatic in origin through fractionation and gamma-glutamyl transferase (GGT) testing. The experts explain how clinical history, medication and supplement use, laboratory findings, and imaging can help distinguish intrahepatic cholestasis from extrahepatic biliary obstruction. They also examine the roles of ultrasound, MRI/MRCP, endoscopic ultrasound, and ERCP when evaluating bile duct dilation, strictures, gallstones, primary sclerosing cholangitis, and possible malignancy. Additional topics include autoimmune testing for conditions such as primary biliary cholangitis, the importance of considering drug-induced liver injury and herbal supplements, and when a liver biopsy may be appropriate after a comprehensive noninvasive workup. This educational podcast provides gastroenterology and hepatology clinicians, advanced practice providers, and other healthcare professionals with a clear clinical framework for evaluating abnormal liver tests and identifying the underlying cause of cholestasis.
GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy
2026/08/18
Thank you to Salix for their support on this podcast episode.
In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing and managing overt hepatic encephalopathy (OHE) in patients with chronic liver disease and cirrhosis. The episode reviews how liver disease may progress from fibrosis to compensated and decompensated cirrhosis, where OHE can emerge as a serious complication. Christina and Janet highlight early signs that may be easy to overlook, including sleep-wake reversal, forgetfulness, personality changes, difficulty concentrating, slowed or slurred speech, balance problems, and challenges completing familiar daily activities.
Drawing on real-world patient scenarios, they discuss common OHE triggers and risk factors, including infection, gastrointestinal bleeding, constipation, dehydration, electrolyte imbalances, prolonged fasting, sedating medications, portosystemic shunting, and sarcopenia. The conversation also emphasizes that OHE is primarily a clinical diagnosis, the importance of involving family members and caregivers in symptom recognition, and the limited role of ammonia testing. Christina and Janet also review nutritional considerations, the use of FIB-4 in broader liver fibrosis assessment, timely follow-up, treatment adherence, and safety conversations surrounding driving, cooking, falls, and other daily activities. For more expert-driven GI and liver disease education, visit the GHAPP Digital Hub and GHAPP ACE app.
FAQ: Counseling Patients on Overt Hepatic Encephalopathy
2026/08/11
Thank you to Salix for their support on this FAQ video module.
In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hepatic encephalopathy (OHE). This educational overview explains how cirrhosis and portal hypertension can reduce the liver’s ability to clear toxins from the blood, potentially leading to changes in thinking, behavior, and daily functioning. Viewers will learn how OHE may present through obvious symptoms—such as disorientation, slurred speech, or severe confusion—or through more subtle changes, including fatigue, irritability, difficulty concentrating, and trouble finding the right words.
This video also highlights the importance of involving caregivers in symptom recognition while preserving patient autonomy, reviewing warning signs that require immediate medical attention, and reinforcing medication adherence through clear patient education. Natalie discusses additional counseling considerations, including avoiding sedating medications and constipation, supporting adequate protein intake and physical activity, and maintaining skeletal muscle mass. Ideal for gastroenterology and hepatology providers and advanced practice providers, this FAQ offers practical strategies for helping patients and families recognize OHE early and work collaboratively with the liver care team to manage this often-reversible complication. For more expert-driven GI and liver disease education, visit the GHAPP Digital Hub and GHAPP ACE app.
FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy
2026/08/04
Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Samantha Ramirez, NP-C, discusses how healthcare professionals can identify and diagnose overt hepatic encephalopathy (OHE) in patients with severe liver disease or cirrhosis. This educational overview highlights early signs that may be subtle or vary between patients, including changes in sleep patterns, slower thinking, difficulty concentrating, irritability, and mild confusion. Samantha also explains how tools such as FIB-4 can contribute to the broader assessment of liver disease severity and help providers understand a patient’s overall clinical picture.
This video reviews OHE as a primarily clinical diagnosis, including the importance of evaluating other potential causes of altered mental status and using the West Haven criteria to describe disease severity. It also explores the impact of OHE on patients and caregivers, as well as the need for strong communication, multidisciplinary collaboration, and continuity of care across inpatient and outpatient settings. Ideal for gastroenterology and hepatology providers and advanced practice providers, this FAQ offers practical guidance for recognizing OHE and supporting patients throughout their care.
For more expert-driven GI and liver disease education, visit the GHAPP Digital Hub and GHAPP ACE app.
Subgroup Analysis: Differences in Maintenance Dosing For UC and CD
2026/07/23
Thank you to Johnson & Johnson for their support on this podcast episode.
In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussion with Amanda Wilhite, PA-C, of Houston Methodist Gastroenterology Associates. The episode explores how healthcare professionals may approach the two FDA-approved subcutaneous guselkumab maintenance dosing options for adults with moderate-to-severe Crohn’s disease and ulcerative colitis: 100 mg every eight weeks or 200 mg every four weeks.
Drawing on data from the Phase 3 GALAXI 2 and 3 Crohn’s disease studies and the QUASAR ulcerative colitis maintenance study, Amy and Amanda discuss how disease severity, inflammatory burden, C-reactive protein levels, endoscopic response, previous advanced-therapy exposure, and individual patient needs may inform maintenance-dosing conversations. They also share real-world perspectives on monitoring treatment response and using the lowest effective recommended dosage to maintain therapeutic response.
For additional IBD education, visit the GHAPP ACE app or digital hub.
Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC
2026/06/30
Thank you to AbbVie for their support of this Medication Review Video Module.
In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the INSPIRE and COMMAND clinical trials evaluating risankizumab for the treatment of moderately to severely active ulcerative colitis. The discussion reviews the trial design, patient populations, induction and maintenance dosing strategies, clinical and endoscopic endpoints, and the rationale behind the approved dosing regimen. The presenters also explain the significance of the phase 2 dose-ranging study and how the clinical development program informed the FDA-approved treatment approach.
Melissa and Jennifer review key efficacy findings, including clinical remission and endoscopic improvement during both induction and maintenance, with a particular focus on outcomes in advanced therapy-naïve patients. They also discuss practical considerations for selecting between the available maintenance doses, the role of top-down treatment strategies, administration using the on-body injector, and recommendations for patient counseling and liver enzyme monitoring. Safety outcomes are reviewed, reinforcing the established safety profile of risankizumab and providing clinicians with practical guidance for incorporating this IL-23 inhibitor into routine clinical practice.
This educational video is designed for gastroenterology nurse practitioners, physician assistants, gastroenterologists, and other healthcare professionals seeking practical insights into evidence-based treatment of ulcerative colitis. Viewers will gain a deeper understanding of the INSPIRE and COMMAND clinical trial data and how these findings can help guide treatment selection, optimize long-term disease control, and support shared decision-making with patients receiving risankizumab.
For more GI and hepatology education, visit the GHAPP Digital Hub and the GHAPP ACE app.
Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease
2026/06/09
Thank you to AbbVie for their support on this Medication Review Video Module.
In this medication review, Sharon Dudley-Brown, CRNP, PhD from Johns Hopkins University and Angelina Collins, MSN, ANP-BC, from the University of California San Diego, provide a comprehensive overview of the SEQUENCE trial, a landmark head-to-head study comparing risankizumab and ustekinumab in patients with moderate to severe Crohn’s disease who had previously failed anti-TNF therapy. The discussion explores the trial design, patient population, dosing strategies, primary and secondary endpoints, and the significance of efficacy assessor blinding in an open-label study.
Sharon and Angelina review key findings demonstrating the superiority of risankizumab over ustekinumab across multiple clinical and endoscopic outcomes, including clinical remission, endoscopic response, corticosteroid-free remission, and long-term disease control. They also discuss the importance of objective disease assessment using centrally read endoscopy and the role of steroid tapering in evaluating treatment success. Safety outcomes are examined, highlighting the absence of new safety signals and reinforcing the established safety profile of risankizumab.
This educational video is designed for gastroenterology nurse practitioners, physician assistants, and other healthcare professionals seeking practical insights into evidence-based treatment selection for Crohn’s disease. Viewers will gain a deeper understanding of how the SEQUENCE study may influence treatment positioning of IL-23 therapies in anti-TNF-experienced patients and how emerging long-term extension data continue to support durable clinical remission and endoscopic improvement with risankizumab.
FAQ: QUASAR Long Term Extension Interim Analysis
2026/06/02
Thank you to Johnson & Johnson for their support on this FAQ Video Module.
In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data evaluating the efficacy and safety of guselkumab in adults with moderate to severe ulcerative colitis. This discussion highlights approximately two years of follow-up data, offering healthcare providers valuable insight into the long-term durability of treatment response, clinical remission, endoscopic improvement, and overall safety outcomes associated with guselkumab maintenance therapy.
Jamie walks through the key findings from the ongoing multicenter extension study, including sustained clinical remission rates, corticosteroid-free remission, endoscopic healing, and histologic-endoscopic mucosal improvement through week 92. The video also reviews the maintenance dosing strategies of guselkumab, including 100 mg every 8 weeks and 200 mg every 4 weeks, and discusses how patients who responded during earlier phases of treatment maintained those responses over time. In addition, the presentation covers important long-term safety findings, including rates of serious infections and adverse events observed throughout the study.
This video is designed for gastroenterology APPs, nurse practitioners, physician assistants, gastroenterologists, and healthcare professionals looking to stay current on emerging ulcerative colitis therapies, long-term biologic data, and evolving treatment goals in inflammatory bowel disease (IBD).
For more educational content on ulcerative colitis, Crohn’s disease, gastroenterology, and hepatology, visit the GHAPP Digital Hub and the GHAPP ACE app.
Podcast sponsorship advertising
Start advertising on GHAPPcast relevant audience podcasts
You may also like to advertise on these Podcasts

4.922782003
First15 Devotional
First15

4.818412000
The Cabral Concept
Dr. Stephen Cabral

4.6254002000
The Glenn Beck Program
Mercury Radio Arts

4.920911196
Toni and Ryan
Toni Lodge and Ryan Jon

4.6652752197
The Charlie Kirk Show
Charlie Kirk

4.8167482000
The GaryVee Audio Experience
Gary Vaynerchuk

4.827591720
Earn Your Happy
Lori Harder | YAP Media

4.762632000
The Lawfare Podcast
The Lawfare Institute

4.715161997
Thrivetime Show | Business School without the BS
Clay Clark

4.98711800
The Adam Mockler Show
MeidasTouch Network